Search for: "BRISTOL-MYERS SQUIBB"
Results 141 - 160
of 863
Sort by Relevance
|
Sort by Date
24 Apr 2019, 3:00 am
In late February, Wellington, which runs $359 billion for Vanguard, announced it would oppose Bristol-Myers Squibb ’s plan to acquire Celgene. [read post]
8 Apr 2019, 9:59 pm
Increases were notanle for Bristol Myers-Squibb and Takeda, while Sanofi and Gilead showed reduced sales. [read post]
2 Apr 2019, 6:53 am
Consolidated World Travel, Inc. is the latest salvo in the conflict over whether the Supreme Court’s personal jurisdiction decision in Bristol-Myers Squibb applies in the class action context. [read post]
30 Mar 2019, 8:49 pm
Neal Dahiya of Bristol-Myers Squibb Company; Michael Flibbert of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; Michael Rosato of Wilson Sonsini Goodrich & Rosati will also address strategies for obtaining, and opposing, appellate standing. [read post]
11 Mar 2019, 7:08 pm
Bristol-Myers Squibb Co. [read post]
11 Mar 2019, 1:03 pm
Supreme Court established limitations on personal jurisdiction over non-resident corporate defendants in state court “mass” actions in Bristol-Myers Squibb Co. v. [read post]
11 Mar 2019, 10:15 am
Bristol-Myers Squibb Co., 919 F.3d 699 (2d Cir. 2019) followed suit and unanimously affirmed snap removal as a procedural vehicle to remove to federal court. [read post]
5 Mar 2019, 9:38 am
Media reports of the Senate Finance hearing called it “political theater,” and it offered lawmakers a chance to vent at execs from AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer, and Sanofi. [read post]
1 Mar 2019, 5:15 am
Bristol-Myers Squibb Co., No. 2017-1694, 2019 U.S. [read post]
12 Feb 2019, 7:56 pm
Bristol-Myers Squibb Co. [read post]
10 Feb 2019, 9:38 pm
February 11, 2019 - "The Next Billion-Dollar Acquisition in Pharma -- A Forward-Looking Patent Analysis on Bristol-Myers Squibb Acquiring Celgene" (LexisNexis) - 2:00 pm (ET) February 12, 2019 - "Biotech Patents and Section 101 Rejections: Meeting Patent Eligibility Requirements -- Leveraging Recent Decisions and USPTO Guidance to Overcome Rejections" (Strafford) - 1:00 to 2:30 pm (EST) February 14, 2019 - "Section 112 Issues in IPR Proceedings:… [read post]
9 Feb 2019, 9:50 pm
LexisNexis will be offering a webinar on "The Next Billion-Dollar Acquisition in Pharma -- A Forward-Looking Patent Analysis on Bristol-Myers Squibb Acquiring Celgene" on February 11, 2019 at 2:00 pm (ET). [read post]
7 Feb 2019, 8:55 pm
By Kevin E. [read post]
7 Feb 2019, 5:36 pm
Bristol-Myers Squibb Co. [read post]
6 Feb 2019, 6:12 am
Regulation of medicinal productsGuestKat Frantzeska Papadopoulou explored the issue of the regulation of orphan drugs in the context of the General Court decision on an action brought by Bristol-Myers Squibb Pharma (BMS) against the Commission and the European Medicines Agency (EMA) in the case T‑329/16: Orphan Drugs, a successful regulation after all? [read post]
5 Feb 2019, 7:34 am
Chairman Chuck Grassley and Ranking Member Ron Wyden sent the invitations to AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., Pfizer and Sanofi. [read post]
30 Jan 2019, 5:44 am
M&A being lumpy and unpredictable as ever, 2019 has opened with a number of notable deals, not least the sale of Celgene to Bristol-Myers Squibb for $95 billion, somewhat defying gloomy predictions for the year. [read post]
29 Jan 2019, 3:12 pm
Several large cases account for much of this effect, including the cases filed against Johnson & Johnson, Facebood, NVIDIA, Bristol-Myers Squibb and Celgene. [read post]
25 Jan 2019, 12:00 am
The first being Bristol Myers Squibb Co’s (BMY) acquisition of Celgene Corp. [read post]
22 Jan 2019, 2:09 am
One case, Bristol-Myers Squibb Co. v. [read post]
